Serotoniteoria virheellinen

Serotoniteoria virheellinen


serotoniteoria virheellinen:
http://medicine.plosjournals.org/perlserv/?request=slideshow&type=table&doi=10.1371/journal.pmed.0020392&id=5510&ct=1&SESSID=721b9cca17320e1eff83b618cb6c307b

http://www.nature.com/news/archive/keyword/antidepressants.html



Jonathan Leo1   and Jeffrey R. Lacasse2
(1) 
Lincoln Memorial University, 6965 Cumberland Gap Parkway, Harrogate, 37752, USA

(2) 
Florida State University (FSU), Tallahassee, USA

Published online: 28 November 2007 
Abstract  The cause of mental disorders such as depression remains unknown. However, the idea that neurotransmitter imbalances cause depression is vigorously promoted by pharmaceutical companies and the psychiatric profession at large. We examine media reports referring to this chemical imbalance theory and ask reporters for evidence supporting their claims. We then report and critique the scientific papers and other confirming evidence offered in response to our questions. Responses were received from multiple sources, including practicing psychiatrists, clients, and a major pharmaceutical company. The evidence offered was not compelling, and several of the cited sources flatly stated that the proposed theory of serotonin imbalance was known to be incorrect. The media can play a positive role in mental health reporting by ensuring that the information reported is congruent with the peer-reviewed scientific literature. 
Keywords  Depression - SSRI - Serotonin 


Jonathan Leo
Email: Jonathan.leo@lmunet.edu


Jonathan Leo, Ph.D.   is an Associate Professor of Neuroanatomy at Lincoln Memorial University in Harrogate TN. He has published numerous articles about mental health covering topics such as the genetic basis of schizophrenia, the serotonin theory of depression, and the pediatric trials of SSRIs. For further questions he can be reached at jonathan.leo@lmunet.edu. 
Jeffrey R. Lacasse, MSW   is a Visiting Lecturer at the Florida State University (FSU). He has published research on practice with children, critical thinking in graduate social work education, and consumer advertising of SSRI antidepressants. He can be reached at jeffreylacasse@mac.com. 
Further Reading 
Antonuccio, D. et al. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, Vol. 68. 



Healy, D. (2006). Let them eat Prozac. New York: New York University Press. 



Kirsch, I. et al. (2002). The emperor’s new drugs: An analysis of the antidepressant medication data submitted to the US FDA.. Prevention and Treatment. Vol. 5. 



Lacasse, J., & Gomory, T. (2003). Is graduate social work education promoting a critical approach to mental health practice? Journal of Social Work Education, 39(3), 383–408. 



Lacasse, J.R. and Leo, J. (2005). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med 2(12): e392. Available at: http://dx.doi.org/10.1371/journal.pmed.0020392. 



Lacasse, J. and Leo, J. (2006). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Medicine. Available at: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020392. 



Leo, J. (2006). The SSRI trials in children. Ethical Human Psychiatry and Psychology, 8(1), 29–41.





more options 
Find 
   
 Within all content

 Within this journal

Export this article 
Export this article as RIS | Text

  

Text 
PDF 
The size of this document is 216 kilobytes. Although it may be a lengthier download, this is the most authoritative online format.
Open: Entire document
HTML 
This offers the quickest access for ease of browsing. Please note that some scientific and mathematical characters may not render as precisely as in PDF versions.




FDA Issues Public Health Advisory on Strattera (Atomoxetine) for Attention Deficit Disorder
The Food and Drug Administration (FDA) today is issuing a Public Health Advisory to alert physicians of reports of suicidal thinking in children and adolescents associated with Strattera, a drug approved to treat attention deficit hyperactivity disorder (ADHD). FDA has also directed Eli Lilly and Company, manufacturer of Strattera, to develop a Medication Guide for patients and caregivers. 

FDA is advising health care providers and caregivers that children and adolescents being treated with Strattera should be closely monitored for clinical worsening, as well as agitation, irritability, suicidal thinking or behaviors, and unusual changes in behavior, especially during the initial few months of therapy or when the dose is changed (either increased or decreased). Patients and caregivers who have concerns or questions about these symptoms should contact their healthcare provider. 
"FDA's action today is another example of the agency acting swiftly to alert the public to significant drug safety information needed to use a drug in a safe manner," said Dr. Steven Galson, Director for the Center for Drug Evaluation and Research, FDA. 

Today's actions follow a review and analysis of 11 clinical trials conducted in children with ADHD and one trial in children with enuresis (bedwetting) that identified an increased risk of suicidal thinking for Strattera. There was one suicide attempt by a patient who received Strattera among the approximately 2,200 patients in the trial. As part of a larger evaluation of psychiatric drugs and suicidality, FDA had requested that the manufacturer conduct a review of its database and clinical trials, which included more than 2200 patients--1350 patients receiving Strattera (atomoxetine) and 851 receiving a placebo. The analysis showed that 0.4% of children treated with Strattera reported suicidal thinking compared to no cases in children treated with the placebo. 

Strattera, manufactured by Eli Lilly, has been on the market since 2002 and has been used in more than two million patients. 
Health care professionals are encouraged to report any unexpected adverse events associated with Strattera directly to Eli Lilly, Indianapolis, Ind. at 1-800-LillyRx or to the FDA MedWatch program at 1-800-FDA-1088; by FAX at 1-800-FDA-0178; by mail to MedWatch, Food and Drug Administration, HFD-410, 5600 Fishers Lane, Rockville, MD, 20857-9787; or online at www.fda.gov/medwatch/report.htm. 
Public Health Advisory
#### 
RSS Feed for FDA News Releases [what's this?]